Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Publikation: Bidrag til tidsskriftKommentar/debatpeer review

DOI

  • Oliver Schnell
  • Tadej Battelino
  • Richard Bergenstal
  • Matthias Blüher
  • Michael Böhm
  • Frank Brosius
  • Richard D. Carr
  • Antonio Ceriello
  • Thomas Forst
  • Francesco Giorgino
  • Bruno Guerci
  • Hiddo J.L. Heerspink
  • Baruch Itzhak
  • Linong Ji
  • Mikhail Kosiborod
  • Nebojša Lalić
  • Michael Lehrke
  • Nikolaus Marx
  • Michael Nauck
  • Helena W. Rodbard
  • Giuseppe M.C. Rosano
  • Peter Rossing
  • Lars Rydén
  • Francesca Santilli
  • Petra Maria Schumm-Draeger
  • Per Olav Vandvik
  • Tina Vilsbøll
  • Christoph Wanner
  • Carol Wysham
  • Eberhard Standl
Vis graf over relationer

The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org).

OriginalsprogEngelsk
Artikelnummer50
TidsskriftCardiovascular Diabetology
Vol/bind21
Udgave nummer1
ISSN1475-2840
DOI
StatusUdgivet - dec. 2022

Bibliografisk note

Funding Information:
The following authors declare competing interests: OS (Oliver Schnell): AstraZeneca, Bayer, Boehringer Ingelheim, Grünethal, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, Wörwag. RB (Richard Bergenstal): Richard M. Bergenstal, MD has received research support, acted as a consultant, or been on the scientific advisory board for Abbott Diabetes Care, Ascensia, Bigfoot Biomedical, CeQur, DexCom, Eli Lilly, Hygieia, Insulet, Medtronic, Novo Nordisk, Onduo, Sanofi, United Healthcare and Zealand. Dr. Bergenstal’s employer, non-profit HealthPartners Institute, contracts for his services and he receives no personal income for these services. MB (Matthias Blüher): Honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. MB (Michael Böhm): Research support (DFG, SFB-TTR 219, S-01): Deutsche Forschungsgemeinschaft; Speakers honoraria: Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Medtronic, Novartis, Servier, Vifor; Advisory board: Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Pfizer, ReCor, Servier, Vifor. HJLH (Hiddo Heerspink): Payments to my institution: AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk; Payments for consultancy to my institution: Dr. L Heerspink reports consulting fees from AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, NovoNordisk, Janssen, Travere Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Institution: AstraZeneca. BI (Baruch Itzhak): Advisory Board, Consultancy, Lectures: Novo Nordisk, Sanofi, Eli Lilly, Bayer, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche Diagnostic, and Medtronic. MK (Mikhail Kosiborod): Research Grant: Astra Zeneca, Boehringer Ingelheim; Consultant/Advisory Board: Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma; Other Research Support: Astra Zeneca; Honorarium: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. NM (Nikolaus Marx): Speaker: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, Bristol-Myers Squibb, Novo Nordisk, Sanofi Aventis; Consultant: AstraZeneca, Bayer, Boehringer Ingelheim / Lilly, MSD, Novo Nordisk; Grant support: Boehringer Ingelheim, MSD. PR (Peter Rossing): Consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Mundipharma, Novo Nordisk, Vifor, and Sanofi Aventis; Research grants from AstraZeneca and Novo Nordisk. LR (Lars Rydén): The authors declare that they have no competing interests. PMSD (Petra-Maria Schumm-Draeger): Grant to institution; Consulting fees: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, Lilly, Novo Nordisk, Sanofi, Hexal, AristoPharma, MSD, Berlin Chemie, Merck, GSK, BMS; Participation on a Data Safety Monitoring Board or Advisory Board: Sanofi, Novo Nordisk, Boehringer Ingelheim, Merck, BMS, AstraZeneca, GSK; Executive Board: European Federation of Internal Medicine; Leadership and executive board: German Society of Internal Medicine; Executive board: Professional German Society of Internal Medicine. POV (Per Olav Vandvik): CEO of MAGIC Evidence Ecosystem Foundation, responsible for MAGICapp as a platform to produce, publish and dynamically update guidelines. MAGIC supports WHO, NICE and other organisations in living guidelines. CW (Christoph Wanner): Grants to institution: Idorsia, Sanofi and Boehringer Ingelheim; Consulting fees: AstraZeneca, Boehringer Ingelheim, Idorsia, Bayer, GILEAD, GSK, and MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, FMC, Chiesi, Lilly, and Vifor; Participation on Data Safety Monitoring Board or Advisory Board: Sanofi and the Australasian Kidney Trials Network; Leadership: European Renal Association. TB (Tadej Battelino), FB (Frank Brosius), RDC (Richard D. Carr), AC (Antonio Ceriello), TF (Thomas Forst), FG (Francesco Giorgino), BC (Bruno Guerci), LJ (Linong Ji), NL (Nebojša Lalić), ML (Michael Lehrke), MN (Michael Nauck), HWR (Helena W. Rodbard), GMCR (Giuseppe M.C. Rosano), FS (Francesca Santilli), TV (Tina Vilsbøll), CW (Carol Wysham), ES (Eberhard Standl) did not declare any competing interests.

Publisher Copyright:
© 2022, The Author(s).

ID: 79243377